Nasus Pharma closed at $3.07 on Oct 30, down 3.76%, 66.4% below its 52-week closing high. Volume of 4.9K shares was 0.26× its 20-day average (below normal).
Split-adjusted performance: -19.5% over one month, +11.6% over six months.
Short interest was 80.4K shares at the Oct 15 settlement, up 2.8% from the prior report (1.2% of float, 4.7 days to cover).
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock.
What is NSRX's market cap?
$35.96M, based on the Oct 30 close of $3.07.
Does Nasus Pharma pay a dividend?
No regular cash dividend has been paid in the last year.
How much of NSRX is sold short?
80.4K shares, 1.2% of float, as of Oct 15, 2026.
About Nasus Pharma
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
